GLASGOW, SCOTLAND- OCTOBER 19: Slot machines are seen in an amusement arcade following the ... [+] announcement of the newly proposed gambling bill which will effect casinos and amusement arcades across the UK, October 19, 2004 in Glasgow, Scotland. The new law if approved by the government will allow casinos with over 1,250 slot machines unlimted jackpots, currently Britain has 126 casinos with slot machine winnings being limited to GBP2,000. (Photo by Christopher Furlong /Getty Images) *** Local Caption ***
Statistics from the North American Foundation for Gambling Addiction and Help estimate that more than 2.6% of Americans struggle with some form of gambling abuse, and many opponents of the expanding sports betting marketplace argue that few measures have been put in place to aid the more than 10 million people battling this addiction.
The overturn of the Professional and Amateur Sports Protection Act (PASPA) the US federal government awarded individual states with the ability to legalize and regulate sports betting in their respective jurisdictions. In doing so, each state has also been given the responsibility to establish clear methods to both prevent, identify, and offer help to those labeled as problem gamblers.
Many sportsbook operators give customers the ability to pause their accounts and to establish self imposed limits, but outside of support groups and dial-in hotlines, few true solutions exist to aid those looking for help.
New research is currently being conducted by a prominent biotech company to explore ketamine as a potential remedy for compulsive behaviors and more specifically gambling addiction.
Awakn Life Sciences has brought on the expertise of Dr. David Nutt, psychiatrist and Edmund J. Safra Professor of Neuropsychopharmacology in the Division of Brain Science, Dept of Medicine, Imperial College London. In doing so, the Awakn team has announced their plans to conduct the first clinical examination of ketamine and gambling addictions.
As a psychopharmacologist, Dr. Nutt has made it his lifes work to study the effects of drugs on the brain. Over the last 15 years I've started studying psychedelics, opens Dr. Nutt, largely because very few people were and I thought it was something someone had to do.
While on this 15-year journey, Dr. Nutt found it particularly interesting that little had been done to advance the research conducted more than a half century ago focused on psychedelics and their impact on brain disorders.
It turned out that studying psychedelics opened up a whole new set of possibilities for treating mental disorders that I hadn't thought of before, partly because I didn't know the literature. It's only now that I've gone back to the 1950s and 60s and discovered there was quite a lot of interest then in treating addiction, particularly alcoholism with psychedelics, then.
Much like gambling, psychedelics cary many unfair social stigmatism, with the act of sports betting just recently making the leap from a taboo, degenerative behavior to a socially acceptable one over the last three years.
Where one could easily argue that the pandemic expedited the spread of sports betting regulation and its public acceptance, the increased emphasis on mental health has also thrust the psychedelic therapeutics industry back into the spotlight. Unbeknownst to many, the two industries might be more connected than one might think.
Our modern imaging work showed that psychedelics disrupt a circuit in the brain that seems to be overactive in conditions like depression. And it's also overactive in conditions where, and probably any condition where people get over engaged in thinking about a single thought.
So in depression, continues Dr. Nutt, depressed people are thinking about mistakes they've made. They're thinking about having low self esteem, etc. And of course, in addiction, people are thinking about the next chance they get to drink or to shoot up or to gamble.
Those in Dr. Nutts field of study often use the term internalizing disorders when labeling this kind of thought process. As he dove deeper, Dr. Nutt had the revelation that the processes of disrupting internal thinking and depression could potentially disrupt the internal thinking in addiction as well.
Dr. Nutt acknowledges that he was not the first to come to this conclusion, referencing the Bogenschutz study in New Mexicos look into alcoholism, and the ongoing clinical trials at Johns Hopkins targeting psychedelics therapeutics for smoking cessation.
So now we've got the neuroscience of psychedelics and some clinical data. Why not bring them together?
The opportunity to make this connection came when Awakn Life Sciences extended Dr. Nutt an offer to join as the groups Chief Research Officer, granting him access to the funding necessary to conduct this research.
Awakn has focused most of its research on the battle against addiction, and gambling addiction presented itself as a prime candidate for the studys efforts. Similarly to the research being conducted at Johns Hopkins for smoking cessation, gambling addiction is viewed as more of a raw addiction that has less outside influences condemning or reinforcing the compulsive action.
We've been studying gambling on the grounds that it's an addiction that isn't confounded by drug use, added Dr. Nutt, suggesting that other chemical dependencies often come with a wide variety of variables that potentially disrupt scientific findings. These substances also produce an obvious biological reaction in the human brain.
Gambling addiction can be difficult to detect, as the problem bettor can often maintain a relatively normal lifestyle. Alcoholics and opiate addicts, for comparison, regularly see their substance dependency impact their personal and professional lives, creating outside stressors and factors that can skew a studys results.
When asked why Awakn had chosen ketamine as the leading candidate, Dr. Nutt points to the most obvious of reasons; Its legal.
Ketamine has long been used as an anesthetic, and the psychoactive chemical is often administered to relieve pain and even induce the loss of consciousness. Given its wide acceptance in the medical community, ketamine was an obvious choice for the study given that it can be both prescribed and put into practice right away.
Ketamine is basically an easily accessible, inexpensive, sort of psychedelic, adds Dr. Nutt. But while it may not be as powerful as psychedelics as drugs like psilocybin or DMT, it's psychedelic enough. It definitely disrupts brain function during the trip, and it seems to be just enough in terms of alcoholism to allow people to recover. So maybe what we can do with setting up this trial is to see if it produces the same disruption in people who are gambling compulsively.
Ketamine is already widely used in the United States to treat depression, but Awakn is seeking to construct a manualized approach to incorporate the chemical into a three-dose psychotherapeutic regimen.
This revolutionary study hopes to provide substantiated evidence and data that supports an abstinence based psychotherapy process using ketamine to curb, and even eliminate these compulsive brain patterns.
What we're hoping is that we can develop and prove that a systematic form of administration and psychotherapy is effective, wed be able to license that as an indicator as a mode of treatment without necessarily having to license the medicine.
Go here to see the original:
- Daily Skimm: Psychedelics, The DOJ, and iMessages - theSkimm - September 15th, 2022
- Inside the UK's new psychedelic drug trial clinic trying to treat depression and anxiety - iNews - September 15th, 2022
- What A Trip: Delix Therapeutics is Treating Mental Health at Scale with Psychoplastogens - Genetic Engineering & Biotechnology News - September 15th, 2022
- HealingMaps Announces $1 Million in Seed Funding to Power Growth in Psychedelic Therapy Industry - Yahoo Finance - September 15th, 2022
- Nav Talks The Moment He Realized He Made It; It Involves Psychedelics - UPROXX - September 15th, 2022
- Psychedelics and Psychedelic-Assisted Psychotherapy - September 7th, 2022
- Preparing for a new era of psychedelic treatment - The Hub at Johns Hopkins - September 7th, 2022
- Toronto is getting a trippy psychedelics immersive exhibition this month - Curiocity - September 7th, 2022
- Xtalks to host upcoming webinar on psychedelic know-how - Mugglehead - September 7th, 2022
- An immersive psychedelic exhibition is opening in Toronto this month | Listed - Daily Hive - September 7th, 2022
- Netflixs How to Change Your Mind Says Drugs Are the Answer Are They Right? - Goalcast - September 7th, 2022
- Yeah, Mental Health, Bro, It Starts With Self-Love | Aaron Rodgers Says His Use Of Psychedelics Has Increased His Passion For Life And The Game Of... - September 7th, 2022
- Delic Executive Chairman Matt Stang Named to World Biz Magazine's Top 100 CEOs in Innovation - Yahoo Finance - September 7th, 2022
- Cannabis and Hallucinogens Are Being Consumed at the Highest Rates on Record by Today's Young Adults - Cannabis Science and Technology - September 7th, 2022
- Aspen considers the value of psychedelics for mental wellness - The Aspen Times - August 29th, 2022
- Oregon's Psychedelics Law Comes Down To Individuals: Which Counties Will Ban Them? - Benzinga - August 29th, 2022
- The Black mothers finding freedom in mushrooms: They give us our power back - The Guardian - August 29th, 2022
- Psychedelic Water CEO Pankaj Gogia Talks About The Future Of Psychedelics - Exclusive - Health Digest - August 2nd, 2022
- Biden Administration Says Task Force Is Needed to Advance Psychedelics Research - Green Entrepreneur - August 2nd, 2022
- Legalizing the trip: One 'shroom advocate's playbook - POLITICO - August 2nd, 2022
- 'The result was a rebirth. I finally got where I wanted to go': Celebs who have tried psychedelics - The Daily Post-Athenian - August 2nd, 2022
- Texas' first Ceremonial Psychedelic Treatment Center WITHIN opens in Austin - PR Web - August 2nd, 2022
- Postdoctoral Research Fellow in Psychedelics, Neurodevelopment and Electrophysiology job with UNIVERSITY OF SYDNEY | 303322 - Times Higher Education - August 2nd, 2022
- Unlimited Sciences Announces Groundbreaking New Study to Observe Ayahuasca's Effects on Trauma - Business Wire - August 2nd, 2022
- Good Trip? How Psychiatrists Got Serious About Using Psychedelics to Treat Mental Health - Robb Report - July 25th, 2022
- The hope and hype of psychedelic therapy - ABC News - July 25th, 2022
- Microdosing Psilocybin Mushrooms May Improve Mental Health and Mood - Healthline - July 25th, 2022
- TDR's Top 5 Psychedelic Developments For The Week Of July 18 - The Dales Report - July 25th, 2022
- Psyched Up: The race to make psychedelic drugs part of mainstream medicine - ABC News - July 25th, 2022
- Keeping the Hippie Dream Alive - The New York Times - July 25th, 2022
- DEA Sued Over Delays To Open Records For Psychedelics And Cannabis - Benzinga - Benzinga - July 25th, 2022
- Trade to Black Podcast: the Senate Vs the Cannabis Administration Opportunity Act - The Dales Report - July 25th, 2022
- Otago academic and comedian takes on the science of getting high - Stuff - July 25th, 2022
- Can mad honey get you high? A bee expert reveals the answer - Inverse - July 25th, 2022
- The promise of psychedelics - Investors' Chronicle - Investors Chronicle - July 14th, 2022
- House Moves to Expand Psychedelic Therapy Research - The Intercept - July 14th, 2022
- Ann Shulgin, pioneer of psychedelics in therapy, dies at 91 - ABC News - July 14th, 2022
- Doctors Urge Access to Psychedelic Therapies in New Mexico - TIME - July 14th, 2022
- States That Have Made Advancements Toward Legalizing Psychedelics - StreetInsider.com - July 14th, 2022
- Canada: 100+ Healthcare Professionals Protest Psilocybin Access Ban For Psychedelics-Assisted Therapy Training - Benzinga - July 14th, 2022
- Optimi Health Finalizes Psilocybin Supply Agreement With Bloom Psychedelic Therapy And Research Centre - Marketscreener.com - July 14th, 2022
- Psychedelics gave me the courage to take charge of my romantic life - Mic - July 7th, 2022
- Goodbye Weed and Acid, Hello Magic Mushrooms - Psychedelic Spotlight - July 7th, 2022
- Meet the Married Couple Trailblazing the Development of Psychedelic Therapies - PR Newswire - July 7th, 2022
- Berkeley's psychedelic rebbe is ready for the first Jewish cannabis retreat - The Jewish News of Northern California - July 7th, 2022
- CaaMTech Collaborates With the Alexander Shulgin Research Institute to Study Shulgin Compounds - Newswire - July 7th, 2022
- Origin Therapeutics adds Clairvoyant Therapeutics to its Portfolio - GlobeNewswire - July 7th, 2022
- Psychedelic-Assisted Therapy & Medicine - Psychedelics.com - July 4th, 2022
- Can microdosing psychedelics improve your mental health? Here's what the science says - ABC News - July 4th, 2022
- Inside Vision Treks: The Mind Armys Psychedelic Retreat Takes Strangers Into The Desert - Forbes - July 4th, 2022
- GOP Congressman's Amendment Would Direct Military To Study Psilocybin And MDMA Benefits For Service Members - Marijuana Moment - July 4th, 2022
- Magic mushrooms: BC production facility one of a handful licensed to grow - CTV News - July 4th, 2022
- 3 Paranormal Experiences That Have Caught The Attention Of Mental Health Researchers - Forbes - July 4th, 2022
- VA Studying Psychedelics As Mental Health Treatment For Veterans - Forbes - June 29th, 2022
- 10 Psychedelics CEOs To Pay Attention To In 2022 - Yahoo Finance - June 29th, 2022
- Secret ancient Andean passageways may have been used in rituals involving psychedelics - Livescience.com - June 29th, 2022
- How psychedelics act on the brain to relieve depression - Daily Maverick - June 29th, 2022
- Magic mushrooms are all the rage. But are they Jewish? - The Guardian - June 29th, 2022
- Treating Stress with Wearable Technology - Psychedelic Spotlight - June 29th, 2022
- Numinus Applies for International Patent Filing of Psychedelics Production Process - PR Newswire - June 29th, 2022
- This Week in Psychedelic Stocks: Compass Pathways Wins Patent Battle, MindMed Patents Candy Flipping, and More! - Psychedelic Spotlight - June 29th, 2022
- Is there a future for psychedelic treatment in Saudi Arabia? - Arab News - June 29th, 2022
- Optimi Health Initiates Agreement With SABI Mind For Therapeutic Supplies Of Psilocybin, MDMA - Marketscreener.com - June 29th, 2022
- Braxia Scientific CEO to Deliver Keynote Address at HC Wainwright & Co. 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and... - June 29th, 2022
- Methylenedioxymethamphetamine (MDMA)-Assisted Therapy in Hawaii: A Brief Review - Cureus - June 29th, 2022
- How an NHL Enforcer Broke His Body and Turned to Psychedelics to Heal His Brain - Rolling Stone - June 22nd, 2022
- The top psychedelic drug developers leading the market - Labiotech.eu - June 22nd, 2022
- Numinus Applies for International Patent Filing of Psychedelics Production Process - Yahoo Finance - June 22nd, 2022
- Two psychedelic-related initiatives may be on the 2022 Colorado ballot - Denver 7 Colorado News - June 22nd, 2022
- Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights - Business Wire - June 22nd, 2022
- SPOTLIGHT IN FOCUS - The Rise of Psychedelic Therapy - Psychedelic Spotlight - June 22nd, 2022
- Rapper Vic Mensa has a more badass fitness routine than you thanks to martial arts, psychedelics and meditation - British GQ - June 22nd, 2022
- What is Ego Death And How Does it Work? - Benzinga - Benzinga - June 22nd, 2022
- Anecdotal Evidence and the Need for Trials of Psychedelics in Headache Disorders: Bryan Roth, MD, PhD - Neurology Live - June 11th, 2022
- Stephen Asma: My father's experience with morphine in hospice showed me the healing joy of altered states - Chicago Tribune - June 11th, 2022
- TDR's Top 5 Psychedelic Developments For The Week Of May 30 - The Dales Report - June 5th, 2022
- Psychedelic Wellness: 5 Magical Benefits of Magic Mushrooms - Longevity LIVE - Longevity LIVE - June 5th, 2022
- 'Magic mushrooms drug could help depression sufferers in the years to come' - Irish Mirror - June 5th, 2022
- Tripping over the potential of psychedelics for autism | Spectrum - Spectrum - June 3rd, 2022
- Can you take the trip out of psychedelics and still treat depression? - New Scientist - June 3rd, 2022